Tirzepatide produces greater average weight loss; semaglutide has the deeper long-term safety record and established cardiovascular outcomes data. Neither is universally "better."
Both are available through Luma Health as compounded medications: semaglutide at $197/month and tirzepatide at $297/month, with a real physician evaluation to help determine the right fit for you.
Semaglutide and tirzepatide are the two leading GLP-1-class medications for weight management in 2026, and patients researching either one eventually run into the same question: which is actually better? The honest answer is that they differ in meaningful ways, and the right choice depends on your specific health profile, not a single "winner."
Mechanism: One Receptor vs. Two
Semaglutide is a GLP-1 receptor agonist — it mimics a single gut hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity. Tirzepatide activates both the GLP-1 and GIP receptors, a dual mechanism that appears to produce somewhat greater average weight loss and larger A1C improvements in head-to-head trial data. The added GIP activity is the core mechanistic difference driving tirzepatide's stronger average results, and it's the reason tirzepatide is sometimes described as a "dual agonist" in clinical literature, distinguishing it from semaglutide's single-receptor approach.
Efficacy: What the Trials Show
| Semaglutide | Tirzepatide | |
|---|---|---|
| Trial | STEP 1 | SURMOUNT-1 |
| Avg. weight loss | ~14.9% at 68 weeks | ~20-22.5% at 72 weeks Higher |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Dosing frequency | Weekly | Weekly |
| Cardiovascular outcomes | Strong — SELECT trial Established | Developing |
| Years on market | Since 2017 (class since 2005) | Since 2022 |
| Luma Health price | $197/month, flat | $297/month, flat |
These percentages are trial averages, not individual guarantees — actual results vary by starting weight, dose, adherence, and individual biology. It's also worth noting that SURMOUNT-5, a head-to-head trial directly comparing tirzepatide against semaglutide in the same patient population, found tirzepatide produced greater average weight loss (approximately 20.2% versus 13.7%) when both medications were compared directly rather than across separate trials with different patient populations, which strengthens confidence in the efficacy difference beyond what separate trials alone can demonstrate.
Switching From One to the Other
Patients who start on one medication and later switch to the other, in either direction, is a common and generally straightforward clinical scenario, not an unusual or risky move to make. If semaglutide's results have plateaued below your goal, or you've experienced side effects that haven't improved with dose adjustment, discussing a switch to tirzepatide with your provider is a reasonable next step. Similarly, if tirzepatide's side effects have been difficult to manage, or you have specific cardiovascular risk factors where semaglutide's more established outcomes data is reassuring, switching to semaglutide is equally reasonable and worth discussing openly with your provider. Your provider will typically start you at an appropriate dose on the new medication based on your current dose and response, rather than starting completely from scratch at the lowest introductory dose available.
Does One Cost More Than the Other?
Through Luma Health, compounded semaglutide is $197/month and tirzepatide is $297/month, both flat regardless of dose. This $100/month difference roughly reflects tirzepatide's more complex manufacturing process (it targets two receptors rather than one, requiring a more involved synthesis) rather than any difference in the underlying value or effectiveness of either medication for an individual patient's specific treatment goals. Brand-name pricing follows a similar pattern — Zepbound's list price runs slightly higher than Wegovy's, and this cost gap persists across most cash-pay and compounded pricing structures industry-wide, not just at any single provider or platform specifically.
If cost is a significant factor in your decision, it's worth discussing with your provider whether the efficacy difference between the two justifies the price difference for your specific situation, since a patient who responds exceptionally well to semaglutide may not need tirzepatide's additional average efficacy to reach their goals, while a patient who needs to lose a larger percentage of body weight may find the additional cost worthwhile given the potential for meaningfully greater results.
Side Effects: Broadly Similar
Both medications share a similar gastrointestinal side-effect profile — nausea, diarrhea, constipation, and vomiting are the most commonly reported, typically most pronounced during dose titration and easing as the body adjusts. Neither medication has a clearly better tolerability record in head-to-head comparisons; individual response varies more than the average difference between the two drugs. Real-world data from large-scale analysis of patient-reported experiences shows broadly similar rates of these common effects between the two medications, with some patients reporting a small additional rate of injection site reactions and muscle aches specifically with tirzepatide, not commonly discussed among semaglutide users at similar rates or frequency.
Both medications also carry the same class-wide warnings: pancreatitis risk (higher with a personal history of pancreatitis), gallbladder disease, and a boxed warning regarding thyroid C-cell tumors seen in rodent studies, contraindicated for patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome specifically. These warnings apply equally to both medications since they stem from the shared GLP-1 mechanism rather than anything unique to either specific drug or manufacturer.
How the Titration Schedules Compare
Both medications follow a gradual dose-escalation schedule designed to minimize gastrointestinal side effects, typically starting at a low introductory dose and increasing every four weeks until reaching a therapeutic maintenance level. Semaglutide's schedule generally spans about 16-20 weeks to reach the highest studied maintenance dose (2.4mg for Wegovy); tirzepatide's follows a similar four-week-per-step cadence toward its own maintenance range (up to 15mg for Zepbound). Neither schedule is meaningfully faster or slower in a way that should drive your choice between the two — the titration pace is about safety and tolerability, not about reaching results more quickly.
What varies more is how individual providers handle titration in practice and manage patients through it. Some follow a rigid, one-size-fits-all schedule regardless of tolerability; better practice is adjusting the pace based on individual side-effect response, slowing down for a patient experiencing significant nausea or maintaining a faster pace for a patient tolerating each increase well without difficulty.
Who Tends to Choose Which, and Why
While the decision should always be individualized rather than based on general patterns, a few tendencies show up in clinical practice worth understanding as general context. Patients with significant weight to lose (more than 20% of body weight as a goal) or coexisting type 2 diabetes often gravitate toward tirzepatide given its somewhat higher average efficacy in trials. Patients with existing cardiovascular disease or strong risk factors sometimes prioritize semaglutide specifically because of its established SELECT trial data demonstrating cardiovascular risk reduction, a body of evidence tirzepatide doesn't yet have to the same degree, simply because it's a newer medication with less time available for equivalent long-term outcome trials to complete and report results. Patients who've tried one medication and experienced difficult side effects sometimes switch to the other, since individual tolerance can vary in ways that aren't fully predictable in advance based on general patient characteristics or population-level trial averages.
Safety Record: Semaglutide's Longer History
The GLP-1 receptor agonist class has been FDA-approved since 2005, and semaglutide specifically since 2017 for diabetes, giving clinicians a longer real-world safety track record. The SELECT trial specifically demonstrated that semaglutide reduces major adverse cardiovascular events in patients with established heart disease — a meaningful data point for that population. Tirzepatide, approved more recently, doesn't yet have an equivalent completed cardiovascular outcomes trial, though one is in progress. This doesn't mean tirzepatide is less safe — its side effect profile and safety data collected so far are broadly reassuring — it simply means semaglutide has had more years and more patients generating real-world safety data, which matters more for some clinical decisions (like a patient with significant cardiovascular risk factors) than for others where the distinction is less clinically relevant to the decision at hand.
Matching the Medication to You
Neither medication is universally "better" — the right choice depends on your specific health profile, weight-loss goals, and how your body responds to each mechanism, something that can't be fully predicted in advance and sometimes requires trying one and adjusting based on your actual experience.
- Have established cardiovascular disease or significant risk factors
- Want the medication with the longest real-world track record
- Have more moderate weight-loss goals
- Prioritize the lower monthly cost
- Have significant weight to lose and want the highest average efficacy
- Have type 2 diabetes and want maximum A1C improvement
- Haven't responded as well as expected to semaglutide
The right choice depends on your BMI, cardiovascular risk factors, diabetes status, and personal response — which is why Luma Health starts every patient with a real medical evaluation from a licensed provider, rather than defaulting everyone to the same medication.
Let a provider help you
choose the right fit
Compounded semaglutide at $197/month or tirzepatide at $297/month, flat — with a real physician evaluation to match the medication to your health profile.
Get Started → Or start your free health assessmentFrequently Asked Questions
Not necessarily. Tirzepatide shows greater average weight loss in trials, but semaglutide has a longer safety track record and established cardiovascular outcomes data via the SELECT trial. The better choice depends on individual health history and goals.
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, a dual mechanism that appears to drive its somewhat greater average efficacy in head-to-head data.
Both share a broadly similar gastrointestinal side-effect profile, most pronounced during dose titration. Neither has a clearly better tolerability record; individual response varies more than the average difference between the two.
Semaglutide, via the SELECT trial, which demonstrated reduced major adverse cardiovascular events in patients with established heart disease. Tirzepatide's equivalent cardiovascular outcomes data is still developing.
This is a reasonable conversation to have with your prescribing provider if you haven't seen the response you expected after an adequate trial period at an appropriate dose. Switching should be guided by your provider rather than done independently.
Neither by default. Every Luma Health patient starts with a real medical evaluation from a licensed provider who considers your BMI, health history, and goals before recommending compounded semaglutide ($197/month) or tirzepatide ($297/month).
Yes, this is a common and generally straightforward clinical scenario. Your provider will typically start you at an appropriate dose based on your current dose and response, rather than starting completely from scratch.
Tirzepatide's more complex manufacturing process, targeting two receptors rather than one, requires a more involved synthesis, which is reflected in its price across both compounded and brand-name formulations.
Not necessarily. Average trial results don't predict your individual response. Some patients respond exceptionally well to semaglutide and don't need tirzepatide's additional average efficacy to reach their specific goals.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PubMed 37385275
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database